Rapid single-nucleotide Polymorphism detection of cytochrome P450 (CYP2C9) and vitamin k epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the Smart-Amplification Process Version 2

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 804-812

  Aomori, Tohru ^a,b   Yamamoto, Koujirou ^a,b   Oguchi Katayama, Atsuko ^c   Kawai, Yuki ^c,d   Ishidao, Takefumi ^c,d   Mitani, Yasumasa ^c,d   Kogo, Yasushi ^c,d   Lezhava, Alexander ^c   Fujita, Yukiyoshi ^b   Obayashi, Kyoko ^b   Nakamura, Katsunori ^a   Kohnke, Hugo ^e   Wadelius, Mia ^e   Ekströ, Lena ^f   Skogastierna, Cristine ^f   Rane, Anders ^f   Kurabayashi, Masahiko ^a   Murakami, Masami ^a   Cizdziel, Paul E ^c   Hayashizaki, Yoshihide ^c,g   Horiuchi, Ryuya ^a,b   more..

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

^d KK DNAFORM   (Japan)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Japan Science and Technology Agency   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE 1; WARFARIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; ASSAY; BLOOD; BLOOD SAMPLING; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; GENE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; VELOCITY; CLASSIFICATION; DOSE RESPONSE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; TIME;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ALIGNMENT; TIME FACTORS; WARFARIN;

EID: 64149111606     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.115295     Document Type: Article

References (40)

1. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Re- search Group. Effect of long-term oral anticoag- ulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
3. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with me- chanical heart valves. N Engl J Med 1995;333: 11-7.
4. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH, for the Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic antico- agulation. A multicenter study. Ann Intern Med 1993;118:511-20.
5. Stroke Prevention in Atrial Fibrillation Investiga- tors. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk pa- tients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lan- cet 1996;348:633-8.
6. Li T, Chang CY, Jin PJ, Lin PJ, Khvorova A, Staf- ford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4.
7. 2. Proc Natl Acad Sci U S A 2006;103:19308-13.
8. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70.
9. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilk- erson HW, Blough DK, et al. Association of vita- min K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in Hong Kong Chi- nese patient population. Pharmacogenet Genom- ics 2005;15:687-91.
10. Sconce EA, Kahn TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regi- men. Blood 2005;106:2329-33.
11. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of coagulation factor, vitamin K epoxide reduc- tase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose re- quirements. Clin Pharmacol Ther 2006;79:291-302.
12. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006;79:197-205.
13. Rieder MJ, Reiner AP, Gare BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplo- types on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
14. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Phar- macol Ther 2006;80:169-78.
15. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphism: a comprehensive re- view of the in-vitro and human data. Pharmaco- genetics 2002;12:251-63.
16. Daly AK, King BP. Pharmacogenetics of oral an- ticoagulants. Pharmacogenetics 2003;13:247-52.
17. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
18. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on war- farin maintenance dose requirement inpatients undergoing anticoagulation therapy. Pharmaco- genetics 1995;5:389-92.
19. Rettie AE, Haining RL, Bajpai M, Levy RH. A com- mon genetic basis for idiosyncratic toxicity of war- farin and phenytoin. Epilepsy Res 1999;35:253-5.
20. U.S. Food and Drug Administration. FDA news: FDA approves updated warfarin (Coumadin) pre- scribing information. http://www.fda.gov/bbs/topics/ NEWS/2007/NEW01684.html (Accessed January 2009).
21. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a pro- spective randomized controlled study. Clin Phar- macol Ther 2008;83:460-70.
22. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circu- lation 2007;116:2563-70.
23. Iwasaki M, Yonekawa T, Otsuka K, Suzuki W, Nagamine K, Hase T, et al. Validation of the loop-mediated isothermal amplification method for single nucleotide polymorphism genotyping with whole blood. Genome Lett 2003;2:119-26.
24. Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, Takova T, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 1999;17:292-6.
25. Compton J. Nucleic acid sequence-based amplifi- cation. Nature 1991;350:91-2.
26. Wabuyele MB, Farquar H, Stryjewski W, Hammer RP, Soper SA, Cheng YW, Barany F. Approaching real-time molecular diagnostics: single-pair fluo- rescence resonance energy transfer (spFRET) de- tection for the analysis of low abundant point mutations in K-ras oncogenes. J Am Chem Soc 2003;125:6937-45.
27. Walker GT, Fraiser MS, Schram JL, Little MC, Nadeau JG, Malinowski DP. Strand displacement amplification-an isothermal, in vitro DNA am- plification technique. Nucleic Acids Res 1992;20: 1691-6.
28. Lizardi PM, Huang X, Zhu Z, Bray-Ward P, Thomas DC, Ward DC. Mutation detection and single- molecule counting using isothermal rolling-circle amplification. Nat Genet 1998;19:225-32.
29. Erice A, Brambilla D, Bremer J, Jackson JB, Kokka R, Yen-Lieberman B, Coombs RW. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000;38:2837-45.
30. Heim M, Meyer UA. Genotyping of poor metab- olisers of debrisoquine by allele-specific PCR am- plification. Lancet 1990;336:529-32.
31. Bassler HA, Flood SJ, Livak KJ, Marmaro J, Knorr R, Batt CA. Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes. Appl Environ Microbiol 1995;61: 3724-8.
32. Bao YP, Huber M, Wei TF, Marla SS, Storhoff JJ, Müller UR. SNP identification in unamplified hu- man genomic DNA with gold nanoparticle probes. Nucleic Acids Res 2005;33:e15.
33. Mitani Y, Lezhava A, Kawai Y, Kikuchi T, Oguchi- Katayama A, Kogo Y, et al. Rapid SNP diagnostics using asymmetric isothermal amplification and a novel mismatch-suppression technology. Nat Methods 2007;4:257-62.
34. Watanabe J, Mitani Y, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, et al. Use of a competi- tive probe in assay design for genotyping of the UGT1A1 28 microsatellite polymorphism by the smart amplification process. Biotechniques 2007; 43:479-84.
35. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. 1991. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Bio- phys Res Commun 1991;175:1112-8.
36. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450 in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
37. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carbox- ylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-15.
38. Tracy TS, Rosenbluth BW, Wringhton SA, Gonza- lez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant in the 4-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 1995;49:1269-75.
39. Hamman MA, Thompson GA, Hall SD. Regioselec- tive and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Phar- macol 1997;54:33-41.
40. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an approach using de- signed tienilic acid derivatives and molecular modeling. Biochemistry 1995;34:10365-75.